LabConnect, Inc.

LabConnect, LLC, based in the US, offers centralized laboratory services and data management solutions tailored for clinical trials, ensuring timely and flexible support through innovative global laboratory networks. LabConnect, LLC specializes in providing comprehensive laboratory services for clinical trials. Founded in 2002, the company is headquartered in Johnson City, US. Under the leadership of CEO Tom Sellig, LabConnect has raised a total of USD 24.

50 mn through various funding rounds, with the most recent being a Series A round in October 2023 led by ABS Capital Partners and supported by BroadOak Capital Partners and Pablo Capital. LabConnect provides a comprehensive suite of services focused on Central Laboratory Services, Functional Service Provider Solutions (FSP), and Data Management specifically for clinical trials. Their core offerings include integrated laboratory solutions that connect clinical trials with modern operations and a global network of innovative laboratories, ensuring timely, flexible, and tailored support. The services address the complexities of clinical research by providing clients with pre-assembled lab kits, real-time sample tracking, and robust data management capabilities.

LabConnect serves a diverse client base including pharmaceutical and biotechnology companies engaged in clinical research across various therapeutic areas such as oncology, vaccines, and cell and gene therapy, with operations extending across North America, Europe, and Asia-Pacific regions. LabConnect's revenue is derived from a transactional structure that primarily involves partnerships with pharmaceutical and biotechnology clients, who utilize their laboratory services and data management solutions throughout the product lifecycle. The company engages in contractual agreements that often involve multi-year partnerships, where clients pay for services based on specific project needs, volume of samples processed, and data management requirements. The pricing structure is generally customized, reflecting the complexity and scale of the services provided.

Key offerings, such as their central lab services and FSP consulting solutions, are bundled into comprehensive service packages that facilitate seamless integration and enhance client operational efficiency within clinical trials. In October 2023, LabConnect secured funding to support its growth initiatives, providing additional time and capital for development while offering liquidity to existing limited partners. The company plans to expand its offerings and reach into new markets, emphasizing growth in Europe and Asia-Pacific by leveraging its innovative laboratory solutions. The funding will be utilized for upcoming product designs aimed at enhancing their data management services, with a focus on improving the efficiency of clinical trials.